Takeshi Sagara, Executive Director, Clinical Development and Medical Affairs, Discovery & Preclinical Research at Taiho, stated: “We believe that future anticancer drug discovery focusing on research and development, not only for advanced cancer, but also for early-stage recurrent cancer, with an eye on the patient journey, will lead to long-term survival and ultimately the overcoming of cancer. We are very pleased to begin this new initiative together with JFCR and NEC toward creating novel cancer vaccines. Utilizing our proprietary patented evaluation models, we will play a key role in evaluating target cancer antigens and identifying clinical trial candidates continuing our challenge in tackling intractable cancers.”